Literature DB >> 15229465

Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Delia Dempsey1, Piotr Tutka, Peyton Jacob, Faith Allen, Kerri Schoedel, Rachel F Tyndale, Neal L Benowitz.   

Abstract

BACKGROUND: Nicotine and a variety of other drugs and toxins are metabolized by cytochrome P450 (CYP) 2A6. Our objective was to evaluate the use of oral nicotine with measurement of the trans-3'-hydroxycotinine (3HC)/cotinine (COT) metabolite ratio as a noninvasive probe of CYP2A6 activity.
METHODS: Sixty-two healthy volunteers received an oral solution of deuterium-labeled nicotine (2 mg) and its metabolite cotinine (10 mg). Plasma nicotine and plasma and saliva cotinine and 3HC concentrations were measured over time.
RESULTS: The 3HC/COT ratio derived from deuterium-labeled cotinine, measured in either plasma (2-8 hours after administration) or saliva (at 6 hours), was strongly correlated with the oral clearance of nicotine (r = 0.76-0.83, depending on the time of measurement). The 6-hour 3HC/COT ratio from nicotine derived from tobacco in 14 smokers was highly correlated with the ratio derived from deuterium-labeled nicotine (r = 0.88) and was also highly correlated with the oral clearance of nicotine (r = 0.90). Two subjects homozygous for inactive CYP2A6 alleles produced no 3HC, confirming the specificity of the metabolite ratio. The 3HC/COT ratio was also highly correlated with the clearance and half-life of cotinine, consistent with the fact that cotinine is also primarily metabolized by CYP2A6.
CONCLUSIONS: The 3HC/COT ratio derived from nicotine either administered as a probe drug or from tobacco use, measured in either plasma or saliva, is highly correlated with the oral clearance of nicotine. The ratio appears to be a useful noninvasive marker of the rate of nicotine metabolism (which is important in studying nicotine addiction and smoking behavior), as well as a general marker of CYP2A6 activity (which is important in studying drug and toxin metabolism).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15229465     DOI: 10.1016/j.clpt.2004.02.011

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  210 in total

1.  Rapid smoking may not be aversive in schizophrenia.

Authors:  Jill M Williams; Kunal K Gandhi; Shou-En Lu; Marc L Steinberg; Neal L Benowitz
Journal:  Nicotine Tob Res       Date:  2012-02-07       Impact factor: 4.244

2.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

3.  Estimation of nicotine dose after low-level exposure using plasma and urine nicotine metabolites.

Authors:  Neal L Benowitz; Katherine M Dains; Delia Dempsey; Lisa Yu; Peyton Jacob
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05       Impact factor: 4.254

4.  Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette.

Authors:  Jill M Williams; Kunal K Gandhi; Shou-En Lu; Supriya Kumar; Junwu Shen; Jonathan Foulds; Howard Kipen; Neal L Benowitz
Journal:  Nicotine Tob Res       Date:  2010-06-28       Impact factor: 4.244

Review 5.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

6.  CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

Authors:  Catherine A Wassenaar; Qian Zhou; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2015-12-15       Impact factor: 2.533

7.  Measures and predictors of varenicline adherence in the treatment of nicotine dependence.

Authors:  Annie R Peng; Mark Morales; E Paul Wileyto; Larry W Hawk; Paul Cinciripini; Tony P George; Neal L Benowitz; Nicole L Nollen; Caryn Lerman; Rachel F Tyndale; Robert Schnoll
Journal:  Addict Behav       Date:  2017-07-12       Impact factor: 3.913

8.  Genetics and smoking.

Authors:  Anu Loukola; Jenni Hällfors; Tellervo Korhonen; Jaakko Kaprio
Journal:  Curr Addict Rep       Date:  2014-03-01

Review 9.  Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?

Authors:  Henry R Kranzler; Rachel V Smith; Robert Schnoll; Afaf Moustafa; Emma Greenstreet-Akman
Journal:  Addiction       Date:  2017-04-21       Impact factor: 6.526

10.  Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.

Authors:  Colin S Cunningham; Megan J Moerke; Martin A Javors; F Ivy Carroll; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.